Med City News

Meghana Keshavan

April 13, 2016


In the wake of all the price gouging antics we’ve seen at Valeant Pharmaceuticals and Turing Pharmaceuticals, Bruce Bloom’s Cures Within Reach provides a breath of fresh, philanthropic air.

The organization’s all about generic drugs – but unlike, say, Martin Shkreli, Bloom’s big idea is to repurpose existing drugs and lessen the overall costs of healthcare. It’s reliant on the idea of a government that pays industry for measurable improvements in public health – which, in Cures Within Reach’s case, involve the treatment of rare diseases.

Bloom spoke today at INVEST, MedCity News’ healthcare investment conference in Chicago. He laid out the mission of Cures Within Reach: To re-examine research and gather information on off-label drug use, and deploy generic drugs to treat rare diseases.

The model has shown some success. For example, Bloom says the organization was able to help bring the treatment cost of the rare disease Autoimmune Lymphoproliferative Syndrome, or ALPS, from $100,000 to $5,000. Researchers found that by repurposing the drug sirolimus, they were able to bring remission rates up to 85 percent – while reducing the spend by $95,000.

 Read the full article here!

Sign up for our eNewsletter today!

 

First Name




Search

Cures Within Reach

Illinois Science+Technology Park

8025 Lamon Avenue, Suite 440

Skokie, IL 60077

(847)745-1252

info@cureswithinreach.org

 

Friday the 26th. copyright 2015 Cures Within Reach.